Detalles de la búsqueda
1.
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
Br J Cancer
; 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38729995
2.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
BMC Cancer
; 23(1): 908, 2023 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37752423
3.
Italian version of the Edmonton Symptom Assessment System (ESAS)-Total Care (TC): development and psychometric validation in patients undergoing cancer treatment or follow-up.
Support Care Cancer
; 30(3): 1923-1933, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623487
4.
Recent advances and future strategies in first-line treatment of ES-SCLC.
Eur J Cancer
; 200: 113581, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301317
5.
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Tumori
; : 3008916241246659, 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38623748
6.
Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities.
Crit Rev Oncol Hematol
; 190: 104109, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37643668
7.
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Clin Breast Cancer
; 23(3): e151-e162, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36599769
8.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Clin Lung Cancer
; 24(7): 631-640.e2, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775370
9.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
10.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
J Hematol Oncol
; 16(1): 119, 2023 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098114
11.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
NPJ Breast Cancer
; 9(1): 27, 2023 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37069173
12.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286305
13.
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Ther Adv Med Oncol
; 15: 17588359231204857, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38130467
14.
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
J Natl Cancer Inst
; 115(7): 796-804, 2023 07 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37042716
15.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Cancers (Basel)
; 13(8)2021 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33921727
16.
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications.
Cells
; 9(12)2020 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33316954
17.
COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study.
ESMO Open
; 5(Suppl 3)2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33158968
Resultados
1 -
17
de 17
1
Próxima >
>>